High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes

NCT03403556 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Atherosclerotic Cardiovascular Disease
Type 2 Diabetes

Interventions

DRUG: Rosuvamibe
DRUG: Monorova

Sponsor

Yuhan Corporation